Literature DB >> 18055551

Amelioration of coxsackievirus B3-mediated myocarditis by inhibition of tissue inhibitors of matrix metalloproteinase-1.

Stephen J Crocker1, Ricardo F Frausto, Jason K Whitmire, Nicola Benning, Richard Milner, J Lindsay Whitton.   

Abstract

Coxsackievirus B3 (CVB3) is a major cause of acute myocarditis, a serious condition that is refractory to treatment. Myocardial damage results in tissue remodeling that, if too extensive, may contribute to disease. Remodeling is achieved by extracellular proteolysis mediated by the matrix metalloproteinases (MMPs), and MMP activity is counterbalanced by tissue inhibitors of MMPs (TIMPs). We show herein that TIMP-1 expression is induced in the myocardium by CVB3 infection. Surprisingly, TIMP-1 knockout mice exhibited a profound attenuation of myocarditis, with increased survival. The amelioration of disease in TIMP-1 knockout mice was not attributable to either an altered T-cell response to the virus or to reduced viral replication. These data led us to propose a novel function for TIMP-1: its highly localized up-regulation might arrest the MMP-dependent migration of inflammatory cells at sites of infection, thereby anatomically focusing the adaptive immune response. The benefits of TIMP-1 blockade in treating viral myocarditis were confirmed by administering, to wild-type animals, TIMP-1-specific siRNA or polyclonal antisera, both of which diminished CVB3-induced myocarditis. These unexpected findings indicate that increased TIMP-1 expression exacerbates, rather than ameliorates, CVB3-induced myocarditis and, thus, that TIMP-1 may represent a target for the treatment of virus-induced heart disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18055551      PMCID: PMC2111101          DOI: 10.2353/ajpath.2007.070179

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  MHC I-dependent antigen presentation is inhibited by poliovirus protein 3A.

Authors:  S B Deitz; D A Dodd; S Cooper; P Parham; K Kirkegaard
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Immunopathology during coxsackievirus infection.

Authors:  J Lindsay Whitton
Journal:  Springer Semin Immunopathol       Date:  2002

3.  Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway.

Authors:  Honglin Luo; Bobby Yanagawa; Jingchun Zhang; Zongshu Luo; Mary Zhang; Mitra Esfandiarei; Christopher Carthy; Janet E Wilson; Decheng Yang; Bruce M McManus
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3.

Authors:  Ulrike Martin; Nadine Jarasch; Matthias Nestler; Alexander Rassmann; Thomas Munder; Simone Seitz; Roland Zell; Peter Wutzler; Andreas Henke
Journal:  Apoptosis       Date:  2007-01-09       Impact factor: 4.677

Review 5.  The group B coxsackieviruses and myocarditis.

Authors:  K S Kim; G Hufnagel; N M Chapman; S Tracy
Journal:  Rev Med Virol       Date:  2001 Nov-Dec       Impact factor: 6.989

6.  Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice.

Authors:  Esther E J M Creemers; Jeniffer N Davis; Andrea M Parkhurst; Peter Leenders; Kathryn B Dowdy; Elizabeth Hapke; Anne M Hauet; Patricia G Escobar; Jack P M Cleutjens; Jos F M Smits; Mat J A P Daemen; Michael R Zile; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-26       Impact factor: 4.733

7.  Cytokine production by Vgamma(+)-T-cell subsets is an important factor determining CD4(+)-Th-cell phenotype and susceptibility of BALB/c mice to coxsackievirus B3-induced myocarditis.

Authors:  S A Huber; D Graveline; W K Born; R L O'Brien
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

Review 8.  Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?

Authors:  E E Creemers; J P Cleutjens; J F Smits; M J Daemen
Journal:  Circ Res       Date:  2001-08-03       Impact factor: 17.367

9.  The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury.

Authors:  Hideo Yasukawa; Toshitaka Yajima; Hervé Duplain; Mitsuo Iwatate; Masakuni Kido; Masahiko Hoshijima; Matthew D Weitzman; Tomoyuki Nakamura; Sarah Woodard; Dingding Xiong; Akihiko Yoshimura; Kenneth R Chien; Kirk U Knowlton
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

10.  Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction.

Authors:  Jun Li; Peter Lothar Schwimmbeck; Carsten Tschope; Sebastian Leschka; Lars Husmann; Susanne Rutschow; Florian Reichenbach; Michel Noutsias; Ursula Kobalz; Wolfgang Poller; Frank Spillmann; Heinz Zeichhardt; Heinz-Peter Schultheiss; Matthias Pauschinger
Journal:  Cardiovasc Res       Date:  2002-11       Impact factor: 10.787

View more
  13 in total

Review 1.  Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.

Authors:  Reid G Hendry; Leanne M Bilawchuk; David J Marchant
Journal:  J Cardiovasc Transl Res       Date:  2014-01-01       Impact factor: 4.132

2.  Wild-type coxsackievirus infection dramatically alters the abundance, heterogeneity, and immunostimulatory capacity of conventional dendritic cells in vivo.

Authors:  Christopher C Kemball; Claudia T Flynn; Martin P Hosking; Jason Botten; J Lindsay Whitton
Journal:  Virology       Date:  2012-05-01       Impact factor: 3.616

3.  Astrocytic tissue inhibitor of metalloproteinase-1 (TIMP-1) promotes oligodendrocyte differentiation and enhances CNS myelination.

Authors:  Craig S Moore; Richard Milner; Akiko Nishiyama; Ricardo F Frausto; David R Serwanski; Roberto R Pagarigan; J Lindsay Whitton; Robert H Miller; Stephen J Crocker
Journal:  J Neurosci       Date:  2011-04-20       Impact factor: 6.167

4.  Testosterone and interleukin-1β increase cardiac remodeling during coxsackievirus B3 myocarditis via serpin A 3n.

Authors:  Michael J Coronado; Jessica E Brandt; Eunyong Kim; Adriana Bucek; Djahida Bedja; Eric D Abston; Jaewook Shin; Kathleen L Gabrielson; Wayne Mitzner; DeLisa Fairweather
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-10       Impact factor: 4.733

5.  Antimicrobial agents for myocarditis: target the pathway, not the pathogen.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Heart       Date:  2009-07-16       Impact factor: 5.994

6.  Enumeration and functional evaluation of virus-specific CD4+ and CD8+ T cells in lymphoid and peripheral sites of coxsackievirus B3 infection.

Authors:  Christopher C Kemball; Stephanie Harkins; J Lindsay Whitton
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

7.  TIMP-1 Promotes the Immune Response in Influenza-Induced Acute Lung Injury.

Authors:  Jenieke R Allen; Lingyin Ge; Ying Huang; Rena Brauer; Tanyalak Parimon; Suzanne L Cassel; Fayyaz S Sutterwala; Peter Chen
Journal:  Lung       Date:  2018-08-30       Impact factor: 2.584

8.  Increased expressions of IL-22 and Th22 cells in the coxsackievirus B3-Induced mice acute viral myocarditis.

Authors:  Qing Kong; Weifeng Wu; Fan Yang; Yanli Liu; Yimin Xue; Mengsha Gao; Wenyin Lai; Xiaofen Pan; Yuluan Yan; Yu Pang; Yuanhua Deng
Journal:  Virol J       Date:  2012-10-11       Impact factor: 4.099

9.  Coxsackievirus B3 inhibits antigen presentation in vivo, exerting a profound and selective effect on the MHC class I pathway.

Authors:  Christopher C Kemball; Stephanie Harkins; Jason K Whitmire; Claudia T Flynn; Ralph Feuer; J Lindsay Whitton
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

10.  Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.

Authors:  Florian Schrötzlmair; Charlotte Kopitz; Birgit Halbgewachs; Fei Lu; Hana Algül; Nils Brünner; Bernd Gänsbacher; Achim Krüger
Journal:  J Cell Mol Med       Date:  2010-12       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.